Link to this page
Human Physiology Simulation Ontology
Last uploaded:
April 7, 2014
Jump to:
Preferred Name | fosamprenavir | |
Synonyms |
FPV |
|
Definitions |
Fosamprenavir (marketed by ViiV Healthcare as fosamprenavir calcium), under the trade names Lexiva (U.S.) and Telzir (Europe) is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir. The FDA approved it October 20, 2003, while the EMEA approved it on July 12, 2004. The human body metabolizes fosamprenavir in order to form amprenavir, which is the active ingredient. That metabolization increases the duration that amprenavir is available, making fosamprenavir a slow-release version of amprenavir and thus reducing the number of pills required versus standard amprenavir. source: http://en.wikipedia.org/wiki/Fosamprenavir |
|
ID |
http://scai.fraunhofer.de/HuPSON#SCAIVPH_00001127 |
|
definition |
Fosamprenavir (marketed by ViiV Healthcare as fosamprenavir calcium), under the trade names Lexiva (U.S.) and Telzir (Europe) is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir. The FDA approved it October 20, 2003, while the EMEA approved it on July 12, 2004. The human body metabolizes fosamprenavir in order to form amprenavir, which is the active ingredient. That metabolization increases the duration that amprenavir is available, making fosamprenavir a slow-release version of amprenavir and thus reducing the number of pills required versus standard amprenavir.
source: http://en.wikipedia.org/wiki/Fosamprenavir
|
|
exact_synonym |
FPV
|
|
label |
fosamprenavir
|
|
prefixIRI |
hupson:SCAIVPH_00001127
|
|
prefLabel |
fosamprenavir
|
|
subClassOf |
Add comment
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |
Create mapping